| Dagnan Behavioral Consultants | |
|
13332 Queen Palm Run N Ft Myers FL 33903-5294 | |
| (239) 822-6886 | |
| Not Available |
| Full Name | Dagnan Behavioral Consultants |
|---|---|
| Speciality | Community/behavioral Health |
| Location | 13332 Queen Palm Run, N Ft Myers, Florida |
| Authorized Official Name and Position | Jaylene Dagnan (OWNER) |
| Authorized Official Contact | 2398226886 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Dagnan Behavioral Consultants 13332 Queen Palm Run N Ft Myers FL 33903-5294 Ph: (239) 822-6886 | Dagnan Behavioral Consultants 13332 Queen Palm Run N Ft Myers FL 33903-5294 Ph: (239) 822-6886 |
| NPI Number | 1194020172 |
|---|---|
| Provider Enumeration Date | 01/21/2011 |
| Last Update Date | 01/21/2011 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194020172 | NPI | - | NPPES |
| 687169198 | Medicaid | FL | |
| 687169196 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | 1010546 (Florida) | Primary |
News Archive
The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.
For high-blood-pressure patients, preventing or reducing enlarged heart (left ventricular hypertrophy or LVH) reduces risk of heart failure. The study is published in the Sept. 4 Annals of Internal Medicine and led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.
Imported resistance has rendered ineffective the two affordable malaria drugs which have been the mainstay of malaria treatment in Africa for forty years, according to experts writing today in the journal Science.
Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.
› Verified 8 days ago